EUVIMEDEUVIMED entdecken
Open Access

IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion

Madelene Lindkvist iD, Anna Göthlin Eremo iD, Geena Varghese Paramel iD, Sheikh Anisul Haque iD, Camilla Rydberg Millrud, Sara Rattik, Caitríona Grönberg iD, David Liberg iD, Allan Sirsjö iD, Karin Fransén iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.039557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Madelene Lindkvist und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden. Hauptthemen laut MEDLINE: Atherosclerosis, Cell Adhesion, Interleukin-1 Receptor Accessory Protein, Endothelial Cells. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blockade of IL1RAP (interleukin 1 receptor associated protein) was recently shown to reduce atherosclerosis in mice, but the effect on human vascular cells is largely unknown. Targeting the IL1RAP coreceptor represents a novel strategy to block the IL1RAP‐dependent cytokines IL (interleukin)‐1, IL‐33, and IL‐36. In the present study, we aimed to evaluate the role of novel antibodies targeting IL1RAP to reduce the effects of IL‐1β, IL‐33, or IL‐36γ in human vascular cells.

Methods

Expression of IL1RAP was observed in human atherosclerotic plaques by immunohistochemistry and microarray and in endothelial cells by flow cytometry. Endothelial cells were cultured with IL‐1β, IL‐33, or IL‐36γ cytokines with or without IL1RAP antibodies and analyzed with Olink proteomics, ELISA, Western blot, and real‐time quantitative polymerase chain reaction. The functional effect of IL1RAP antibodies on endothelial cells were analyzed with adhesion and permeability assays.

Results

Olink proteomics showed inhibition of the inflammatory proteins LIF (leukemia inhibitory factor), OPG (osteoprotegerin), CCL4 (C‐C motif chemokine ligand 4), and MCP‐3 (monocyte chemoattractant protein 3) by IL1RAP‐blockade in endothelial cells after IL‐1β stimulation. In addition, the IL1RAP antibodies inhibited IL‐1β, and IL‐33 induced IL‐6 and IL‐8 secretion. Secretion of MCP‐1 (monocyte chemoattractant protein 1) was induced by IL‐1β, IL‐33, and IL‐36γ, and subsequently was inhibited by IL1RAP antibodies. Similar effects were found on mRNA expression level. Endothelial expression of the adhesion markers ICAM1 , VCAM1, and SELE were significantly reduced by IL1RAP antibodies, and neutrophil adhesion to endothelial cells induced by IL‐1β and IL‐33 was reduced by IL1RAP blockade. In human atherosclerotic lesions, IL1RAP expression correlated with markers of inflammation like IL6 , IL8, and MCP1 .

Conclusions

IL1RAP‐targeting antibodies can reduce the expression of inflammatory cytokines and markers of adhesion in endothelial cells, which may be of importance for future putative targeted treatments against cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCell AdhesionInterleukin-1 Receptor Accessory ProteinEndothelial CellsAntibodiesHumansInterleukin-33Plaque, AtheroscleroticCells, CulturedInterleukin-1betaInterleukin-1Human Umbilical Vein Endothelial Cells

Stichwörter der Autor:innen

HUVECsIL‐1IL‐33IL‐36endothelial cells

Substanzen

Interleukin-33Interleukin-1 Receptor Accessory ProteinIL1RAP protein, humanIL33 protein, humanInterleukin-1betaInterleukin-1Antibodies

Autor:innen und Institutionen

  • Cardiovascular Research Centre, Faculty of Medicine and Health Örebro University Örebro Sweden.
  • School of Medical Sciences, Faculty of Medicine and Health Örebro University Örebro Sweden.
  • Department of Clinical Research Laboratory, School of Medical Sciences, Faculty of Medicine and Health Örebro University Örebro Sweden.
  • Cantargia AB Lund Sweden.

ORCID-Profile: Madelene Lindkvist, Anna Göthlin Eremo, Geena Varghese Paramel, Sheikh Anisul Haque, Caitríona Grönberg, David Liberg, Allan Sirsjö, Karin Fransén

Zitieren

APA

Lindkvist, M., Göthlin Eremo, A., Paramel, G. V., Anisul Haque, S., Rydberg Millrud, C., Rattik, S., Grönberg, C., Liberg, D., Sirsjö, A., & Fransén, K. (2025). IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039557

Vancouver

Lindkvist M, Göthlin Eremo A, Paramel GV, Anisul Haque S, Rydberg Millrud C, Rattik S, et al. IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039557

BibTeX
@article{Lindkvist2025,
  author = {Lindkvist, Madelene and Göthlin Eremo, Anna and Paramel, Geena Varghese and Anisul Haque, Sheikh and Rydberg Millrud, Camilla and Rattik, Sara and Grönberg, Caitríona and Liberg, David and Sirsjö, Allan and Fransén, Karin},
  title = {IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.039557}
}
Kostenlos starten →